Stealth BioTherapeutics to Report Third Quarter Financial Results on Thursday, November 11
Stealth BioTherapeutics Corp (Nasdaq: MITO) announced that it will report its third quarter 2021 financial results on November 11 before the market opens. A conference call will take place at 8:30 am ET to discuss the results and provide a business update. Investors can listen to the call by dialing (877)-407-0989 or accessing a live audio webcast on the company's investor website. Stealth is focused on therapies for mitochondrial dysfunction, with its lead product candidate, elamipretide, targeting rare diseases linked to this condition.
- Scheduled reporting of Q3 financial results could indicate transparency and engagement with investors.
- Potential of elamipretide to treat rare metabolic cardiomyopathies and other mitochondrial diseases.
- None.
BOSTON, Nov. 4, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report third quarter 2021 financial results on Thursday, November 11, before the market opens.
Management will host a conference call at 8:30 am ET that day to discuss the financial results and provide a general business update. The call can be accessed by dialing (877)-407-0989 (domestic) or (201)-389-0921 (international) and referencing conference ID 13723309. A live audio webcast of the event can be accessed by visiting the Investors & News section of Stealth's Investor website, https://investor.stealthbt.com/. A replay of the webcast will be archived on Stealth's website for 30 days following the event.
About Stealth
We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the heart, the eye, and the brain. We believe our lead product candidate, elamipretide, has the potential to treat both rare metabolic cardiomyopathies, such as Barth, Duchenne muscular dystrophy and Friedreich's ataxia, rare mitochondrial diseases entailing nuclear DNA mutations, as well as ophthalmic diseases entailing mitochondrial dysfunction, such as dry age-related macular degeneration and Leber's hereditary optic neuropathy. We are evaluating our second-generation clinical-stage candidate, SBT-272, and our new series of small molecules, SBT-550, for rare neurological disease indications following promising preclinical data. We have optimized our discovery platform to identify novel mitochondria-targeted compounds which may be nominated as therapeutic product candidates or utilized as mitochondria-targeted vectors to deliver other compounds to mitochondria.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-report-third-quarter-financial-results-on-thursday-november-11-301415576.html
SOURCE Stealth BioTherapeutics Inc.
FAQ
When will Stealth BioTherapeutics report its Q3 2021 financial results?
What can investors expect from the conference call on November 11, 2021?
What is the ticker symbol for Stealth BioTherapeutics?
What are the main products of Stealth BioTherapeutics?
